Loading stock data…
NYXH
$1.34-0.05 (-3.60%)
After Hours$1.35+0.01 (+0.75%)· Last close Jun 9
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nyxoah SA in the Healthcare sector is trading at $1.34. Wall Street consensus targets $8.90 (4 analysts), implying a +564.2% move over the next 12 months. The stock is currently near its 52-week low of $1.28, remaining 69.3% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 18 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +564.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 18) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$1.34
Potential Downside
0%
Whystock Fair Value$1.34
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Buy
Mean target$8.90+564.2%
Range$4.92 – $12.81
Fundamentals
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The c...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-233.18%
Volume
Today's trading volume
970,477
Recent News
Why Is NYXH Stock Falling Today?
The company priced its stock offering on Friday at a steep discount, with proceeds to be used to expand commercialization activities in the United States.
Nyxoah SA (NYXH) Q1 2026 Earnings Call Highlights: Strong U.S. ...
Nyxoah SA (NYXH) reports a 25% sequential U.S. revenue increase, while addressing production yield issues impacting gross margins.
Nyxoah Q1 Earnings Call Highlights
Nyxoah (NASDAQ:NYXH) reported 13% sequential worldwide net revenue growth in the first quarter of 2026, driven primarily by continued adoption of its Genio system in the United States, where the company is in its second full quarter of commercialization. Chief Executive Officer Olivier Taelman said
Nyxoah SA (NYXH) Reports Q1 Loss, Tops Revenue Estimates
Nyxoah (NYXH) delivered earnings and revenue surprises of +19.88% and +4.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Nyxoah SA (NYXH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Nyxoah (NYXH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.